We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-0.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.89B
AUM Growth
-$643M
Cap. Flow
-$392M
Cap. Flow %
-5.69%
Top 10 Hldgs %
36.47%
Holding
178
New
7
Increased
49
Reduced
68
Closed
19

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$49.8M
2
ALGN icon
Align Technology
ALGN
+$27.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
VEEV icon
Veeva Systems
VEEV
+$13.1M
5
LEGN icon
Legend Biotech
LEGN
+$7.46M

Top Sells

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$159M
2
CI icon
Cigna
CI
+$30.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.6M
4
ELV icon
Elevance Health
ELV
+$26.9M
5
DXCM icon
DexCom
DXCM
+$26.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
2 Industrials 0.84%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
26
Jazz Pharmaceuticals
JAZZ
$15.5B
$83.4M 1.21%
569,857
-186,779
-25% -$27.6M
EXAS
27
DELISTED
Exact Sciences
EXAS
$83.1M 1.21%
1,225,042
-86,973
-7% -$5.59M
PACB icon
28
Pacific Biosciences
PACB
$447M
$81.4M 1.18%
7,026,106
+547,181
+8% +$5.44M
HCA icon
29
HCA Healthcare
HCA
$82.3B
$80.1M 1.16%
303,786
-27,520
-8% -$6.99M
OPCH icon
30
Option Care Health
OPCH
$3.41B
$77.6M 1.13%
2,442,185
+11,763
+0.5% +$352K
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$73.2M 1.06%
1,109,382
+5,165
+0.5% +$298K
TNDM icon
32
Tandem Diabetes Care
TNDM
$1.17B
$72.8M 1.06%
1,793,763
+2,313
+0.1% +$95.8K
EVH icon
33
Evolent Health
EVH
$654M
$71.1M 1.03%
2,191,147
+207,494
+10% +$6.56M
MGNX icon
34
MacroGenics
MGNX
$285M
$68.9M 1%
9,609,913
+630,000
+7% +$3.79M
RLAY icon
35
Relay Therapeutics
RLAY
$4.34B
$68.7M 1%
4,172,600
-32,220
-0.8% -$578K
PEN icon
36
Penumbra
PEN
$12.5B
$66.4M 0.96%
238,172
+12,355
+5% +$3.15M
CLDX icon
37
Celldex Therapeutics
CLDX
$2.77B
$64.8M 0.94%
1,800,000
– –
CRL icon
38
Charles River Laboratories
CRL
$10.8B
$61M 0.89%
302,446
+12,469
+4% +$2.83M
SWAV
39
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$61M 0.89%
281,376
+33,760
+14% +$6.58M
ACCD
40
DELISTED
Accolade Inc
ACCD
$58.1M 0.84%
4,041,801
+364,524
+10% +$4.13M
ARVN icon
41
Arvinas
ARVN
$517M
$58.1M 0.84%
2,127,000
-23,412
-1% -$740K
ALGN icon
42
Align Technology
ALGN
$12.7B
$57.2M 0.83%
171,140
+91,946
+116% +$27.1M
INSM icon
43
Insmed
INSM
$23.5B
$56.1M 0.81%
3,293,102
+15,895
+0.5% +$309K
IDXX icon
44
Idexx Laboratories
IDXX
$44.8B
$55.5M 0.81%
110,928
+2,106
+2% +$1.01M
BIO icon
45
Bio-Rad Laboratories Class A
BIO
$8.15B
$54.5M 0.79%
113,739
+2,581
+2% +$1.21M
OM icon
46
Outset Medical
OM
$77.9M
$53.5M 0.78%
193,784
+4,205
+2% +$1.54M
EXEL icon
47
Exelixis
EXEL
$14.1B
$50.6M 0.73%
2,609,000
-64,500
-2% -$1.12M
TMO icon
48
Thermo Fisher Scientific
TMO
$198B
$49.8M 0.72%
86,333
+3,004
+4% +$1.69M
VEEV icon
49
Veeva Systems
VEEV
$31.7B
$48.3M 0.7%
262,985
+76,728
+41% +$13.1M
TMDX icon
50
Transmedics
TMDX
$2.56B
$47.7M 0.69%
629,484
-52,574
-8% -$3.64M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2023 Portfolio in Review

As of Q1 2023, Bellevue Group held 178 positions worth $6.89B, down 8.5% from $7.53B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group withdrew a net $392M in Q1 2023, closing 19 positions and reducing 68 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $159M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Verona Pharma worth $5.27M.

  • Bellevue Group's largest Q1 2023 buy was Verona Pharma: 262,683 shares worth $5.27M.
  • Bellevue Group added most to Medtronic in Q1 2023, an estimated $49.8M increase.
  • Bellevue Group's biggest Q1 2023 reduction was Cigna, cutting an estimated $30.6M.
  • Bellevue Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $159M.
  • Bellevue Group's ten largest holdings make up 36% of its $6.89B portfolio in Q1 2023.
  • Bellevue Group opened 7 new positions and closed 19 in Q1 2023.
  • Bellevue Group's portfolio value fell 8.5% quarter-over-quarter to $6.89B.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.